ORIC logo

ORIC ORIC Pharmaceuticals, Inc.

NASDAQ Global Select · Biotechnology · Healthcare

$7.61
+0.09 (+1.20%)

ORIC Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative treatments for cancer patients across the United States. The company's pipeline includes several key clinical-stage drug candidates. ORIC-533 is an oral small molecule designed to inhibit CD73, addressing resistance to both chemotherapy and immunotherapy. Another candida…

Market Cap: $788.80Mwww.oricpharma.com

Price

$13.50+43.01%
$7.50$9.50$11.50$13.50
Apr 29Aug 7

Social Signal Score

52
5d
—
30d
50
3 mentions
+0.0%
60d
53
10 mentions
+0.0%
90d
54
13 mentions
+0.0%
news: 13

Analyst Ratings

12 analysts
Buyconsensus
Strong Buy 0Buy 12Hold 0Sell 0Strong Sell 0
Avg price target$22.2+191.7%
Low $14Median $26High $27
Current Consensus

Revenue

$0.00
$0.00
Mar 2019Sep 2026

Analyst Estimates

FY2025
$-1.52
$-1.58–$-1.49
10 analysts
FY2026
$-1.53
$-1.61–$-1.44
3 analysts
FY2027
$-1.72
$-1.93–$-1.40
11 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Jacob Chacko
Sector
Healthcare
Industry
Biotechnology
Employees
111
Beta
0.98
Country
US
Piotroski score
1 / 9 (Weak)
Altman Z-score
13.31
www.oricpharma.com